erdafitinib,cisplatin,cetrelimab
janssen
['bladder', 'cetrelimab', 'erdafitinib', 'cisplatin']
#asco2023: abstract recommendations from for #bladdercancer exciting findings from #asco2023 for bladder cancer treatment: 1 #erdafitinib plus #cetrelimab showed a higher overall response rate (54.5%) compared to erdafitinib alone (44.2%) in cisplatin-ineligible 
Leader GU @InstitutoRoffo #GU #RCC #prostate #bladder #testis #GUcsm #clinicaltrials #Immunotherapy #PrecisionMedicine #OncoAlert #OncoReporte
Views Mine